Abstract Library

#3465 Opposite treatment approach in two institutes identifies primary tumor resection to be associated with improved disease specific mortality in patients with stage IV small intestinal neuroendocrine tumors (SI-NET) vs watch-and-wait strategy

Introduction: SI-NET often present with metastatic disease. There is an ongoing debate whether or not to perform primary tumor resection (PTR) in stage IV SI-NET.

Conference:

Presenting Author: Levy S

Authors: Levy S, Arthur J, Banks M, Kok N, Fenwick S,

Keywords: SI-NET, surgical approach, stage 4, instrumental variable,

#3050 Radioembolization for Neuroendocrine Liver Metastases: An Institutional Case Series, Systematic Review and Meta-Analysis

Introduction: Neuroendocrine liver metastases are clinically challenging and often non-resectable due to their frequent disseminated distribution. Radioembolisation with yttrium-90 labelled microspheres represents an emerging modality for NELM.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Clift A

Authors: Clift A, Frilling A, Braat A, Alsafi A, Wasan H,

Keywords: liver, metastases, radioembolization, yttrium, selective internal radiation therapy,

#2731 177Lu-DOTATATE Plus 166Ho-Radioembolization in Patients with Neuroendocrine Tumours; A Single Center, Prospective, Interventional, Non-Comparative, Open Label, Phase II Study (HEPAR PLuS Study)

Introduction: The liver is the most commonly affected organ in metastatic neuroendocrine disease and is the most incriminating factor for patient survival. Additional treatment of liver disease with radioembolization may improve outcome in NET patients with bulky residual liver disease after PRRT.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Braat A

Authors: Braat A, Rutger B, Van Rooij R, Braat M, Wessels F,

Keywords: NET, PRRT, SIRT, Radioembolization, Ho-166, Neuroendocrine tumor,

#2023 International Multicentre Retrospective Study on the Safety of Radioembolization with Yttrium-90 Resin Microspheres after Systemic Radionuclide Therapy in Neuroendocrine Tumors

Introduction: In the treatment metastatic neuroendocrine tumours (mNET) safety concerns exist when treating patients with radioembolization (RE) after prior systemic radionuclide therapy (SRT)

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Braat A

Authors: Braat A, Kappadath C, Ahmadzadehfar H, Stothers C, Deroose C,

Keywords: PRRT, Radioembolization, neuroendocrine tumors, metastasis, radionuclide treatments,

#1683 International Multicenter Retrospective Study on the Efficacy and Toxicity of Radioembolization in Neuroendocrine Tumours with Yttrium-90 Resin Microspheres

Introduction: Radioembolization (RE) is applied worldwide in patients with liver-dominant metastatic neuroendocrine tumours (mNET). Current literature is of poor quality and based on small heterogeneous populations

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Braat A

Authors: Braat A, Mahvash A, Stothers C, Deroose C, Frilling A,

Keywords: neuroendocrine tumors, radioembolization, sirt,